Company Overview
Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -52.97% |
| 6 Months: | -5.60% |
| 3 Months: | +33.33% |
| 1 Month: | +12.30% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)57.89 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 57.6% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | NSRX Nasus Pharma Ltd. PHARMA | 3.88 | -3.43 | $45.45M | 0.00% | - | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 2.04M | 1.15M | 1.08M | 4.90M |
| Operating Income | -2.04M | -1.15M | -1.08M | -4.90M |
| EBITDA | -2.13M | -1.15M | -1.08M | -4.90M |
| Interest Expense | 18.00K | 49.00K | 29.00K | - |
| Pretax Income | -2.15M | -1.00M | -1.55M | -5.80M |
| Tax Provision | - | - | - | - |
| Net Income | -1.71M | -1.05M | -1.53M | -5.86M |
| Diluted EPS | -0.24 | -0.20 | -0.22 | -0.72 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | 417.00K | 444.00K | 717.00K | 5.00M |
| Current Assets | 417.00K | 444.00K | 457.00K | 4.86M |
| Cash & Equivalents | 154.00K | 193.00K | 284.00K | 1.24M |
| Inventory | - | - | - | - |
| Receivables | - | - | - | - |
| Total Liabilities | 3.20M | 4.24M | 3.93M | 2.24M |
| Current Liabilities | 3.20M | 4.24M | 3.93M | 2.16M |
| Long Term Debt | - | - | - | - |
| Total Debt | 1.57M | 2.46M | 1.80M | 118.00K |
| Total Equity | -2.79M | -3.80M | -3.21M | 2.77M |
| Shares Outstanding | 9.06M | 9.06M | 9.06M | 9.02M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -1.21M | -1.03M | -665.00K | -4.92M |
| Investing Cash Flow | -160.00K | 0 | 0 | -3.01M |
| Financing Cash Flow | 1.24M | 1.05M | 770.00K | 8.92M |
| Capital Expenditure | - | - | - | -14.00K |
| Free Cash Flow | -1.21M | -1.03M | -665.00K | -4.93M |
| Net Change in Cash | -133.00K | 26.00K | 105.00K | 988.00K |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | - | - | - | - |
| Net Margin % | - | - | - | - |
| ROE % | 61.4% | 27.7% | 47.7% | -211.6% |
| ROCE % | 73.3% | 30.2% | 33.6% | -172.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Balyasny Asset Management LP | 7.67% | 898.47K | $3.17M |
| 2 | Cable Car Capital, LP | 5.26% | 616.08K | $2.17M |
| 3 | Velan Capital Investment Management LP | 3.07% | 359.39K | $1.27M |
| 4 | Hudson Bay Capital Management Lp | 1.15% | 134.77K | $475.74K |
| 5 | Bleichroeder LP | 0.77% | 89.85K | $317.16K |
| 6 | Citadel Advisors Llc | 0.19% | 22.00K | $77.67K |
| 7 | Xtx Topco Ltd | 0.14% | 16.64K | $58.74K |
| 8 | Renaissance Technologies, LLC | 0.10% | 12.20K | $43.06K |
| 9 | Morgan Stanley | 0.01% | 1.00K | $3.53K |
| 10 | Caitong International Asset Management Co., Ltd | - | 4 | $14 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NSRX
A company developing nasal allergy medicine will present in New York - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxPMGJSZkxndENzUUhUQzA2QkVyUGJ1MlZLamt1a3BSQWVYUTlMdEswRDV5SWVJa0dQV1BmX0JoY2hBU2pGRVE4QUpheUgxa0VmRGQtekZXaWNDcnczWWZmcGlWSjUwOF9GcGsxQWhUc0JQM3gwWGRLTWE5TkxEQ3JUcW1SeWltZXdBaVNoT1…
Nasus Pharma (NSRX) Stock Forecast and Price Target 2026 - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE05QUdYOFJBdGJrLWQ3ek9HN3J0a1ExSnl6TUR3Qzkzc1RZUDhlWDVyNnhWT0tPVm5vZXpsNEIwVnVnVmd6QU4weE0zQ0ZlSmJVbm5ic1lJNTNDR3c0c0tjMXRRc1NjZmlWV3FGQ3B3?oc=5" target="_blank">Nasus Pharma (NSRX)…
$NSRX stock is up 22% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxNZ0IzLTdjRVFvZGowakswOFZzVnlHSGM1SHlqV2o5WjZVMDlna0FPMXlVWDFrYlZldzNCU3l3NjJSRVMycXA0OG5KYWNneG5uMk5zcWxYNEpLdnJDbVNBOEVsTVFBQkFpQXliV2N5NUhxWmc5VkFTZmtqbFlkSjAxMXM3YktndjVtSDZkdk…
NSRX - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE9MZmIzbVBnRkI2OEdCVjVJZG1kejJHVi1nZjhVT01sUTg1TXUwZjU4ZG9mTy1uZnNiYWx5Y3hJRUl5ajNabVE?oc=5" target="_blank">NSRX</a> <font color="#6f6f6f">Finviz</font>…
NSRX Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTE9FMHRPalp1YVl0UDFYYU1VSlJTX25kY1JHS1B6TzhBYkF3SFRYeWZaREFEU2RVWlY4QXY1LVk4SXU4UXBWai1ROWpVelFaMjN3UWcxcjNDN0M2OWhicnFmNXZNdGZKcy1kZ001UHRQMmVUNmJmMjBJ?oc=5" target="_blank">NSRX Fo…
A $750,000 sale bonus? Nasus Pharma (NSRX) puts CEO pay to a shareholder vote - Stock Titan
<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxNd3BiSjlEeklNZFBWWDJTVnBBczQ4eVdORjY0NVpPei1IYjNObUluTVo4UE5aS3pMcGx0bllxZ3pxbWZLdUFPMjl3TEFIYVZHdEJneGNMLXN0MUd3dTFtaGNYekpna2Jvb0hrNVZOQnNINVlBRlFiYVg1YUdMSXdfbDNPQU5waDdWMURid2…
NSRX — Frequently Asked Questions
What is the current share price of Nasus Pharma Ltd. (NSRX)?
As of 2026-09-19 21:16 PDT, Nasus Pharma Ltd. (NSRX) trades at $3.88 on NYSE American. Its 52-week range is $2.01 to $9.15.
What is the market capitalisation of NSRX?
Nasus Pharma Ltd. (NSRX) has a market capitalisation of $45.45M on NYSE American.
What is the P/E ratio of NSRX?
NSRX trades at a trailing price-to-earnings (P/E) ratio of -3.43. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 3.76.
Is NSRX a good stock to buy?
This page provides a data-driven analysis of Nasus Pharma Ltd. (NSRX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.